Published on:

Yaz Lawsuits: FDA Will Look More Closely

Like every plaintiff”s lawyer and their mother, we have been trying to attract potential Yaz lawsuit clients. I think the Yaz cases are going to be good and I think when all is said and done, Yaz/Yasmin is going to come off the market and Bayer is going to reach a global settlement in these cases.

The FDA may indirectly push that ball along. The FDA now says it will take another look at the risks that accompany Yaz/Yasmin. The big risk that Yaz lawsuits allege that are going to make up most of the larger Yaz settlements should these cases resolve are the deep vein thrombosis (DVT)/ pulmonary embolism (PE).


The FDA will look to see if Yaz/Yasmin has a higher risk of blood clots and death. The FDA takes this on by looking at new and old studies of Yaz/Yasmin which hopefully includes looking at Bayer’s raw data and event coding. But the FDA goes a step further, commissioning its own study exploring the association of blood clots with hormonal contraception. The FDA says that the results of that study are “currently being finalized and reviewed.” I’m looking forward to hearing what they come up with.

Again, we are looking closely at potential Yaz/Yasmin lawsuits. If you think you may have one, call 800-553-8082 or get a free on-line consultation.